Indeed, 8 studies described prospective virtual screening protocols combining several in silico methods for the prediction of dual PPARα/γ agonist ligands with therapeutic applications for T2D (70–72) and of PPARγ ligands (74–78). Here, PPARA is linked to type 2 diabetes mellitus.